Subcutaneous Pharmacokinetics of Belatacept

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Pharmacokinetics, Bioavailability, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Abatacept

Criteria

Inclusion Criteria:

• Men and women ages 18 to 65 years old

• Subjects must weigh less than or equal to 100 kg

Exclusion Criteria:

• Inability to tolerate injections or IV infusions

• autoimmune disorders

• TB

• herpes

• HCV

• HBV

• HIV

• bacterial or viral infection

• history of cancer